NYSE:BSXMedical Equipment
A Look at Boston Scientific’s Valuation Following Breakout Electrophysiology Growth and Expanded FDA Approval
Boston Scientific (BSX) reported strong third-quarter 2025 financial results, with its Electrophysiology division seeing remarkable growth due to the FARAPULSE Pulsed Field Ablation System and expanded FDA approval. Product launches and strategic moves also contributed to this momentum.
See our latest analysis for Boston Scientific.
Boston Scientific’s recent product launches and surging Electrophysiology sales have helped maintain momentum in what is becoming a more competitive space, even...